NCT01632332View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 9, 2012

Primary Completion Date

March 24, 2014

Study Completion Date

July 9, 2018

Conditions
HER2-positive Breast CancerMale Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast Cancer
Interventions
BIOLOGICAL

HER-2/neu peptide vaccine

Given ID

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic

Collaborators (1)

Marker Therapeutics, Inc.
All Listed Sponsors
collaborator

Marker Therapeutics, Inc.

INDUSTRY

lead

Mayo Clinic

OTHER

NCT01632332 - Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer | Biotech Hunter | Biotech Hunter